Exact(2)
In contrast to these findings, 43 patients discontinuing the SSRI paroxetine experienced significantly more discontinuation symptoms, such as insomnia, muscle aches, dizziness, and nausea, than another 61 patients who continued treatment with the SSRI.
Patients in the sirolimus-based CNI-free group had a significantly higher incidence of PTDM and a trend toward more discontinuation due to drug toxicity.
Similar(58)
Etoricoxib produced significantly more discontinuations for oedema and hypertension (Table 2).
There were more discontinuations for lack of efficacy with celecoxib at licensed doses than with NSAIDs, balanced by fewer adverse-event discontinuations or gastrointestinal-adverse-event discontinuations.
Etoricoxib had fewer discontinuations than NSAIDs for lack of efficacy, clinical adverse events, and laboratory and gastrointestinal adverse events, but with more discontinuations because of hypertension and oedema.
There were more discontinuations in the sham arm than the ranibizumab arm (18.4 and 9.8%, respectively) (supplementary Fig. 2, available in an online appendix).
There were more discontinuations due to adverse events in the duloxetine 60 mg/day and 120 mg/day treatment groups compared to the placebo group.
In the AIM study [ 22], adverse events led to more discontinuations in the abatacept group than in the placebo group (4.2% versus 1.8%).
Thirty-one patients discontinued (9, 16 and 6 patients in the placebo, 5 mg and 10 mg groups, respectively) with more discontinuations in the 5 mg group than in the 10 mg group.
However, there were more discontinuations due to adverse effects in the duloxetine 120 mg once daily arm, which suggests that a dosing regimen of duloxetine 60 mg twice daily may be better tolerated.
There were more discontinuations in the placebo group, primarily because of lack of efficacy (n = 29); the difference from the number of discontinuations due to lack of efficacy in each of the two abatacept groups (13 and 12) was statistically significant (P < 0.05).
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com